PRESENCE OF BOTH STIMULATING AND BLOCKING TYPES OF TSH‐RECEPTOR ANTIBODIES IN SERA FROM THREE PATIENTS WITH PRIMARY HYPOTHYROIDISM

A case report of three patients with primary hypothyroidism who had potent TSH‐binding inhibitor immunoglobulins (TBII) and both thyroid stimulating (TSAb) and thyroid stimulation‐blocking antibodies (TSBAb) has been described. Two patients displayed symptoms and signs indistinguishable from those in primary myxoedema (cases 1 and 2), and another patient had a history of Graves'disease (case 3). TBII, TSAb and TSBAb activities were 90.0, 1084.2 and 94.5% in case 1, 91.5, 826.6 and 95.8% in case 2, 76.0, 230.0 and 95.0% in case 3, respectively (normal range, < 11.0%, < 145.0 and < 22.0%, respectively. The results indicate that both stimulating and blocking types of TSH‐receptor antibodies exist in these patients. The possible mechanism whereby hypothyroidism developed has been discussed.

[1]  徳田 康孝.  Inhibition of thyrotropin-stimulated iodide uptake in FRTL-5 thyroid cells by crude immunoglobulin fractions from patients with goitrous and atrophic autoimmune thyroiditis , 1990 .

[2]  Y. Shong,et al.  Inhibition of thyrotropin-stimulated adenylate cyclase activation and growth of rat thyroid cells, FRTL-5, by immunoglobulin G from patients with primary myxedema: comparison with activities of thyrotropin-binding inhibitor immunoglobulins. , 1989, Acta endocrinologica.

[3]  A. Miyauchi,et al.  Coexistence of thyroid-stimulating and thyroid-blocking antibodies in a patient with Graves' disease who had transient hypothyroidism. , 1988, The American journal of medicine.

[4]  H. Hatabu,et al.  Inhibition of thyrotropin-stimulated iodide uptake in FRTL-5 thyroid cells by crude immunoglobulin fractions from patients with goitrous and atrophic autoimmune thyroiditis. , 1988, The Journal of clinical endocrinology and metabolism.

[5]  H. Kitaoka,et al.  DEVELOPMENT OF HYPERTHYROIDISM FOLLOWING PRIMARY HYPOTHYROIDISM: A CASE REPORT WITH CHANGES IN THYROID‐RELATED ANTIBODIES , 1988, Clinical endocrinology.

[6]  H. Hatabu,et al.  Comparison of thyroid stimulating activities measured by cyclic AMP production, those by radioiodine uptake in FRTL-5 cells and TSH-binding inhibitory activities in patients with hyperthyroid and euthyroid Graves' diseases. , 1988, Acta endocrinologica.

[7]  H. Hatabu,et al.  Evaluation of TSH-receptor antibodies as prognostic markers after cessation of antithyroid drug treatment in patients with Graves' disease. , 1988, Acta endocrinologica.

[8]  Y. Iwatani,et al.  IN‐VITRO CONVERSION OF BLOCKING TYPE ANTI‐TSH RECEPTOR ANTIBODY TO THE STIMULATING TYPE BY ANTI‐HUMAN IgG ANTIBODIES , 1987, Clinical endocrinology.

[9]  B. Glaser,et al.  THYROTROPHIN RECEPTOR BLOCKING ANTIBODIES: INCIDENCE, CHARACTERIZATION AND IN‐VITRO SYNTHESIS , 1987, Clinical endocrinology.

[10]  J. Konishi,et al.  A sensitive and practical assay for thyroid-stimulating antibodies using FRTL-5 thyroid cells. , 1987, Acta endocrinologica.

[11]  S. Nagataki,et al.  The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment. , 1987, The Journal of clinical endocrinology and metabolism.

[12]  J. Konishi,et al.  Optimization and clinical assessment of a radioreceptor assay for thyrotropin-binding inhibitor immunoglobulins. , 1987, Endocrinologia japonica.

[13]  M. Katakura,et al.  Evidence for thyrotropin (TSH)-blocking activity in goitrous Hashimoto's thyroiditis with assays measuring inhibition of TSH receptor binding and TSH-stimulated thyroid adenosine 3',5'-monophosphate responses/cell growth by immunoglobulins. , 1987, The Journal of clinical endocrinology and metabolism.

[14]  J. Konishi,et al.  Inhibition of thyrotropin-induced growth of rat thyroid cells, FRTL-5, by immunoglobulin G from patients with primary myxedema. , 1987, The Journal of clinical endocrinology and metabolism.

[15]  P. Buckland,et al.  CHARACTERIZATION OF TSH ANTAGONIST ACTIVITY IN THE SERUM OF PATIENTS WITH THYROID DISEASE , 1986, Clinical endocrinology.

[16]  J. Konishi,et al.  A sensitive and practical assay for thyroid-stimulating antibodies using crude immunoglobulin fractions precipitated with polyethylene glycol. , 1986, The Journal of clinical endocrinology and metabolism.

[17]  J. Konishi,et al.  Paired determination of thyroid-stimulating and TSH-binding inhibitory activities in patients with Graves' disease during antithyroid drug treatment. , 1986, Acta endocrinologica.

[18]  J. Mckenzie,et al.  Studies on multiple thyroid cell membrane-directed antibodies in Graves' disease. , 1985, The Journal of clinical investigation.

[19]  J. Konishi,et al.  Primary myxedema with thyrotrophin-binding inhibitor immunoglobulins. Clinical and laboratory findings in 15 patients. , 1985, Annals of Internal Medicine.

[20]  B. Smith,et al.  A RECEPTOR ASSAY FOR THE MEASUREMENT OF TSH RECEPTOR ANTIBODIES IN UNEXTRACTED SERUM , 1984, Clinical endocrinology.

[21]  S. Filetti,et al.  Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin. , 1984, The Journal of clinical endocrinology and metabolism.

[22]  P. Vitti,et al.  Monoclonal antibodies to the thyrotropin receptor: stimulating and blocking antibodies derived from the lymphocytes of patients with Graves disease. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Mckenzie,et al.  Clinical significance of assay of thyroid-stimulating antibody in Graves' disease. , 1980, Annals of internal medicine.

[24]  K. Bech,et al.  TSH and thyroid stimulating antibodies (TSAb) activate thyroid adenylate cyclase through different pathways. , 2009, Acta medica Scandinavica. Supplementum.

[25]  K. Bech,et al.  THYROID ADENYLATE CYCLASE STIMULATING IMMUNOGLOBULINS IN THYROID DISEASES * , 1979, Clinical endocrinology.

[26]  D. Williams,et al.  Human thyroid adenyl cyclase-stimulating activity in immunoglobulin G of patients with Graves' disease. , 1976, The Journal of clinical endocrinology and metabolism.